Erez Aminov - 28 May 2024 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MIRA	Incentive Stock Options (right to buy)	Award	$0	+379,000	+152%	$0.000000	629,000	28 May 2024	Common Stock	379,000	$0.8400	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on May 28, 2024.
F2	The stock options were issued to the Reporting Person on May 28, 2024, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). The stock options vested in full and became exercisable immediately upon issuance on the grant date, May 28, 2024.
F3	Represents 50,000 stock options that were issued to the Reporting Person on April 28, 2023 that were vested in full and became exercisable on the same date, pursuant to a grant under the Issuer's Plan at an exercise price of $5.00 each, (ii) 150,000 stock options that were issued to the Reporting Person on August 17, 2023, pursuant to a grant under the Issuer's Plan which vested in full on August 17, 2023 at an exercise price of $6.50 each, (iii) 50,000 stock options that were issued to the Reporting Person on August 17, 2023 that vested in full and became exercisable on April 28, 2024, pursuant to a grant under the Issuer's Plan at an exercise price of $6.50 each, and (iv) 379,000 stock options that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Issuer's Plan at an exercise price of $0.84 each.